Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)

WT1, peptide, high risk, immunotherapy, immune response.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Guenther Koehne, Sean Devlin, Neha Korde, Sham Mailankody, Landau Heather, Hani Hassoun, Alexander Lesokhin, Nikoletta Lendvai, David Chung, Nicholas Sarlis, Sergio Giralt, Ola Landgren Source Type: research